PCDH17

Across TCGA pan-cancer cohorts, PCDH17 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PCDH17 data layer compared with 22 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PCDH17 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PCDH17 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

LUAD and GBM are the cancer types where PCDH17 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.857	1.000	.003	45	view →
GBM	OS	Tertile	All	0.614	0.260	.001	18	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

PCDH17–LUAD (OS)

Open the LUAD breakdown →